SERUM ANTIBODIES AGAINST GroEL AS AN ADDITIONAL RISK BIOMARKER OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY.

Background: The level of heat shock protein 60 (Hsp60) is elevated in tumor cells compared with normal prostate epithelium. Hsp60 is involved in tumor growth, invasion, and metastasis and is considered as a biomarker for cancer diagnosis and prognosis.

Aim: To study the level of antibodies against prokaryotic homolog of human Hsp60 (GroEL) in prostate cancer (PCa) patients as an additional risk marker for the prediction of biochemical recurrence after radical prostatectomy (RP).

LONG-TERM RADICAL PROSTATECTOMY ONCOLOGIC OUTCOMES IN PATIENTS WITH CLINICALLY LOCALLY ADVANCED PROSTATE CANCER: A SINGLE-CENTER STUDY.

Background: Prostate cancer (PCa) is the second most frequently diagnosed cancer in males worldwide and placed fifth in cancer mortality among males. Between 14-24% of PCa patients have newly diagnosed advanced stages, which paradoxically has remained stable over time.

Aim: To estimate and compare long-term radical prostatectomy (RP) oncologic outcomes in patients with clinically locally advanced prostate cancer (LAPCa), to determine the prognostic significance of common clinical-pathological parameters.

6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage.

The detection of prostate cancer (PCa) biomarkers in bodily fluids, a process known as liquid biopsy, is a promising approach and particularly beneficial when performed in urine samples due to their maximal non-invasiveness requirement of collection. A number of gene panels proposed for this purpose have allowed discrimination between disease-free prostate and PCa; however, they bear no significant prognostic value. With the purpose to develop a gene panel for PCa diagnosis and prognosis, the methylation status of 17 cancer-associated genes were analyzed in urine cell-free DNA obtained from 31 patients with PCa and 33 control individuals using methylation-specific polymerase chain reaction (MSP).

[BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].

There were examined 87 patients, suffering prostatic gland diseases, in whom the level of general prostate-specific antigen (PSA) in the blood have constituted 0.5 – 30 ng/ml. In 27 of them prostatic gland diseases were not revealed, in 28 – prostatic cancer was diagnosed, and in 32 – benign prostatic hyperplasia.

[IDENTIFICATION OF A NEW DIAGNOSTIC MARKERS OF PROSTATIC CANCER, USING NOTI-MICROCHIPS].

The biopsy material specimens were investigated in 33 patients, examined for the prostatic cancer suspicion. In accordance to the morphological investigation data, in 15 patients a benign prostatic hyperplasia was verified, and in 18--pancreatic adenocarcinoma. NotI-Microchips of 180 clones of the third chromosome were used for determination of epigenetic changes.

[PROGNOSTIC STRATIFICATION OF CLINICALLY LOCALLY SPREAD CANCER OF PROSTATIC GLAND].

In 2002 — 2015 yrs in the clinic radical prostatectomy was performed in 403 patients for prostatic cancer, including those having stage cТ3 — in 102 (25.3%). Basing on analysis of main risk factors, a model of prognostic stratification of clinically locally spread prostatic cancer on three groups was created: with low risk — in the absence of data, confirming invasion into seminal vesicles (stage cТ3а), the prostate—specific antigen (PSA) content less than 20 ng/ml, degree of cellular differentiation of tumor (Glisson's index) in accordance to biopsy data — 6 and less; with intermediate risk — while presence of one of unfavorable prognostic factors (stage cТ3b), PSA 20 ng/ml and more, Glisson's index 7 and more; with high risk — while presence of two and more unfavorable prognostic factors.